Further investigations will be necessary to determine whether anti-RRP8 and anti-TNP1 antibodies can be used as biomarkers of LN disease activity, and for evaluating the performance of panels of LN-associated autoantibodies for diagnosis, monitoring, and prognostic stratification of patients with LN. This evidence concerns the gene RRP8 and lobular neoplasia.